(Reuters) – Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.
Allergan, which has repeatedly rejected offers from Valeant Pharmaceuticals International Inc (VRX.TO), would consider a takeover proposal that values the company at above $200 per share, some of these people said.
Actavis, which held informal conversations with Allergan in recent months about a possible combination, would like to take a hard look at buying the company and could reach out to its management team as soon as this week to reiterate its interest, one of the sources said.
There has been no formal engagement between the two companies yet, the sources said, asking not to be named because the matter is not public.
Separately, Valeant and its partner William Ackman are planning to boost their offer for Valeant by $15 per share to about $191 per share, the Wall Street Journal reported on Tuesday citing people familiar with the matter.
Allergan, while fighting off Valeant’s advances, did not reach out to other alternative buyers and instead focussed on identifying opportunities for revenue growth and cost cuts internally. But it is aware of competing interest from other drugmakers, particularly from Actavis, the sources said.
The emergence of Actavis as a serious rival suitor adds another twist to the months-long takeover battle between Valeant and Allergan. The Canadian drugmaker’s bid already has attracted controversy because it is backed by activist investor Ackman, leading to a legal challenge from Allergan which has accused the two parties of insider trading.
Shares of Allergan ended 1.7 percent higher at $186.20 on the New York Stock Exchange after rising more than 3 percent on the news, valuing the company at more than $55 billion. Actavis closed at $243.39 for a market capitalisation of roughly $64 billion. Shares of Valeant fell 2.5 percent, putting the value of its existing cash and stock offer for Allergan at $175.94 per share, or $52.8 billion based on shares outstanding.
Analysts have an average price target of around $200 per share for Allergan, with the price ranging from $174 to $240 per share, according to a Thomson Reuters poll of 16 analysts. Representatives for Allergan and Actavis declined to comment.
Actavis’ continued pursuit of Allergan comes as the takeover target faces a Dec. 18 special shareholder meeting, at which top Allergan investor Ackman’s Pershing Square Capital Management hopes to replace a majority of the company’s board.
Pershing Square has teamed up with Valeant to pursue a takeover of Allergan, and is hoping to install new board members who could be more receptive to a takeover by the Canadian drugmaker. Actavis, which regularly reviews potential acquisitions, considers Allergan as the best opportunity currently and is hoping to engage in friendly discussions, the sources said.
Industry executives have said Actavis would be a better cultural fit for Allergan because the companies’ respective chief executives, Brent Saunders and David Pyott, believe in focussing on research and development, while Valeant CEO Mike Pearson is known for cost cutting.
A large part of Allergan’s business is ophthalmology, an area that Saunders is familiar with after serving as CEO of Bausch & Lomb. Valeant acquired Bausch & Lomb last year.
DEFENSIVE ACQUISITION UNLIKELY
Valeant and Pershing Square offered to buy Allergan on April 22 but Allergan has said the offer undervalued the company. Since then Allergan has announced cost cuts and said it was looking for acquisitions while trying to persuade shareholders they were better off remaining independent.
But the possibility of Allergan making a potentially large acquisition has faced significant opposition from shareholders who feared such a deal would make the company too big and expensive for Valeant. Allergan had held on and off discussions with Salix Pharmaceuticals Ltd (SLXP.O) about buying the drugmaker for more than $10 billion in cash, people familiar with the matter said previously.
A cash takeover would not have required a shareholder vote and could have put Allergan out of Valeant’s reach. Those discussions stalled in part because Allergan considered Salix’s valuation as high, and while the company continues to look at other deal opportunities, the likelihood of it striking a big acquisition before the Dec. 18 shareholder meeting is low, the sources said.
(Reporting by Soyoung Kim and Nadia Damouni; additional reporting by Caroline Humer; Editing by Richard Chang and Lisa Shumaker)
GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]
Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]
Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]